You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
By identifying these biomarkers, the partners hope to better predict which SMM patients will progress to multiple myeloma and ultimately develop new treatments.
With at-home testing and online, patient-centered reports, the CureCloud initiative sets out to break down barriers to targeted treatment options while building a broad patient dataset.
Investigators plan to tap into large genomic and other datasets with an in silico patient to simulate drug responses, uncover treatment targets, and assess therapies.
GNS Healthcare will apply its AI and simulation technology to data from the CoMMpass study in search of insights on disease progression and drug response.
A structural variant analysis based on genome sequences for almost 800 multiple myeloma cases suggests a IgL translocation present in nearly 10 percent of patients may inform survival.